1. |
Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology, 2015, 61(6): 1968-1977.
|
2. |
Rossi M, Merli M, Lai Q, et al. Outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transplant Proc, 2007, 39(6): 1895-1897.
|
3. |
Xu X, Zheng SS, Liang TB, et al. Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int, 2004, 3(3): 341-344.
|
4. |
Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg, 2002, 235(4): 533-539.
|
5. |
Ji N, Weng D, Liu C, et al. Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget, 2016, 7(4): 4369-4378.
|
6. |
Sangro B, Mazzolini G, Ruiz M, et al. A phaseⅠ clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther, 2010, 17(12): 837-843.
|
7. |
Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol, 2009, 10(1): 35-43.
|
8. |
Rojas-Martínez A, Manzanera AG, Sukin SW, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther, 2013, 20(11): 642-649.
|
9. |
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334(11): 693-699.
|
10. |
Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85(12): 1726-1732.
|
11. |
樊嘉, 周俭, 徐泱, 等. 肝癌肝移植适应证的选择: 上海复旦标准. 中华医学杂志, 2006, 86(18): 1227-1231.
|
12. |
孙超, 罗清波, 卢修贤, 等. 符合米兰标准和杭州标准的肝癌肝移植受者预后回顾性分析. 中华移植杂志(电子版), 2015, 9(2): 9-13.
|
13. |
刘召波, 栗光明. 肝移植术后肝癌复发防治进展. 临床肝胆病杂志, 2021, 37(2): 267-271.
|
14. |
卢倩, 童翾, 汤睿. 肝癌肝移植转化治疗策略进展. 临床肝胆病杂志, 2021, 37(2): 257-259.
|
15. |
谢炎, 张炜琪, 孙纪三, 等. 超米兰标准肝癌肝移植术后肿瘤复发的综合治疗与局部治疗的疗效比较. 肝癌电子杂志, 2021, 8(3): 12-16.
|
16. |
王媒西, 赵圆圆, 魏来, 等. mTOR抑制剂对预防肝癌肝移植术后肿瘤复发的疗效分析. 中华器官移植杂志, 2021, 42(9): 529-533.
|
17. |
王媒西, 赵圆圆, 杨博, 等. 不同抗肿瘤治疗方法对肝癌肝移植术后复发转移的疗效比较. 器官移植, 2021, 12(3): 302-308.
|
18. |
秦小琰, 刘彦尧, 康权. 肝癌肝移植术后复发转移的防治策略和靶向免疫治疗. 器官移植, 2022, 13(2): 271-276.
|
19. |
Shetty K, Dash C, Laurin J. Use of adjuvant sorafenib in liver transplant recipients with high-risk hepatocellular carcinoma. J Transplant, 2014, 2014: 913634. doi: 10.1155/2014/913634.
|
20. |
Waidmann O, Hofmann WP, Zeuzem S, et al. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. J Hepatol, 2011, 54(2): 396-398.
|
21. |
黄帆. 肿瘤免疫治疗与肝癌肝移植. 肝胆外科杂志, 2021, 29(4): 257-261.
|
22. |
李照, 朱继业. 免疫治疗时代下的肝癌肝移植. 临床肝胆病杂志, 2021, 37(2): 249-252.
|
23. |
高祥, 王祎. 腺病毒载体在肿瘤基因治疗和基因疫苗领域的应用研究进展. 生物医学转化, 2021, 2(1): 83-88, 94.
|
24. |
Prieto J, Qian C, Hernandez-Alcoceba R, et al. Gene therapy of liver diseases. Expert Opin Biol Ther, 2004, 4(7): 1073-1091.
|
25. |
Li N, Zhou J, Weng D, et al. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007, 13(19): 5847-5854.
|
26. |
Zhu R, Weng D, Lu S, et al. Double-dose adenovirus-mediated adjuvant gene therapy improves liver transplantation outcomes in patients with advanced hepatocellular carcinoma. Hum Gene Ther, 2018, 29(2): 251-258.
|